CSIMarket Company Name, Ticker, Suppliers, else..
 
Relay Therapeutics Inc   (NASDAQ: RLAY)
Other Ticker:  
 
 
Price: $3.1000 $0.04 1.307%
Day's High: $3.155 Week Perf: -5.78 %
Day's Low: $ 3.06 30 Day Perf: -20.92 %
Volume (M): 2,590 52 Wk High: $ 10.72
Volume (M$): $ 8,029 52 Wk Avg: $6.04
Open: $3.09 52 Wk Low: $3.02



 Market Capitalization (Millions $) 444
 Shares Outstanding (Millions) 143
 Employees 280
 Revenues (TTM) (Millions $) -
 Net Income (TTM) (Millions $) -338
 Cash Flow (TTM) (Millions $) -20
 Capital Exp. (TTM) (Millions $) 2

Relay Therapeutics Inc
Relay Therapeutics Inc is a biotechnology company that focuses on developing new treatments for cancer and other diseases. The company uses a combination of computation, experimental biology, and medicinal chemistry to discover and design potential therapies. Their approach involves studying the movement and interaction of proteins within cells to identify targets for drug development. By understanding how proteins behave, Relay Therapeutics aims to create precise and effective therapies that can address the underlying causes of diseases. The company's goal is to deliver breakthrough treatments and improve patients' lives.


   Company Address: 399 Binney Street Cambridge 2142 MA
   Company Phone Number: 370-8837   Stock Exchange / Ticker: NASDAQ RLAY


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
BCRX        5.37% 
BEAM        6.29% 
CRSP        4.03% 
DNA        5.77% 
EDIT        5.7% 
KRYS        3.15% 
• View Complete Report
   



Product Service News

Relay Therapeutics Reports Promising Interim Data for RLY-2608 in Advanced Breast Cancer A Step Forward in Targeted T...

Published Mon, Dec 30 2024 2:44 AM UTC

In the evolving landscape of oncology therapies, Relay Therapeutics has announced notable updates regarding its investigational drug, RLY-2608, in combination with fulvestrant for the treatment of patients with PI3K-mutated, hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) metastatic breast cancer. The company?s recent interim data h...
Clinical Study

Promising Interim Data on RLY-2608 A Breakthrough in Progression-Free Survival by Relay Therapeutics

Published Mon, Sep 9 2024 10:55 AM UTC

In a pivotal moment for precision oncology, Relay Therapeutics Inc. (NASDAQ: RLAY) has announced encouraging interim data from its ongoing trial of RLY-2608, a targeted therapy designed for patients with advanced solid tumors. The findings signal a potential step forward in the quest for more effective cancer treatments, particularly in terms of improving progression-free su...
Clinical Study

Upcoming Webcast by Relay Therapeutics Insights into RLY-2608 Data on September 9, 2024

Published Fri, Sep 6 2024 8:06 PM UTC

Abstract: Relay Therapeutics has announced a webcast slated for September 9, 2024, during which the company will share crucial data regarding its investigational drug RLY-2608. This article examines the significance of this upcoming event within the context of drug development, particularly in precision medicine and oncology. Relay Therapeutics, a biotechnology company at...
Clinical Study

Relay Therapeutics and Pfizer Join Forces in Trailblazing Clinical Trial to Combat Aggressive Breast Cancer Subtypeb...

Published Wed, Jun 5 2024 8:05 PM UTC

Relay Therapeutics and Pfizer Collaborate on Groundbreaking Clinical Trial for PI3K-Mutated HR+/HER2- Metastatic Breast CancerIn an exciting development in the fight against metastatic breast cancer, Relay Therapeutics has announced a clinical trial collaboration with pharmaceutical giant Pfizer. This joint effort aims to explore the potential benefits of combining Atirmoci...
Relay Therapeutics Inc

Relay Therapeutics Inc Sees Astonishing 7226.163% Surge in Revenue, Setting Industry Standards



Relay Therapeutics Inc, a leading biotechnology company, has recently reported impressive financial results for the third quarter of 2023. These results, including significant revenue growth and improved earnings per share, are expected to have a positive impact on the company's future. Let's delve deeper into the facts and consider how they may influence Relay Therapeutics Inc moving forward.
1. Stellar Revenue Growth:
During the third quarter of 2023, Relay Therapeutics Inc experienced a remarkable 7226.163% growth in revenue. The company's revenue surged from $0.34 million in the corresponding quarter of the previous fiscal year to $25.20 million. Moreover, the sequential growth also reflects a doubling of revenue by 21078.151% from $0.12 million in the prior quarter. This exceptional revenue growth showcases Relay Therapeutics Inc's ability to leverage its pharmaceutical advancements, placing it ahead of its industry peers, who experienced a 5.96% average growth during the same period.









Help

About us

Advertise
CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2025 CSIMarket, Inc. All rights reserved.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com